title: Epilepsy-related employment prevalence and retirement incidence in the German working population: 1994-2009.
abstract: Epilepsy-related employment prevalence and retirement incidence were investigated in the German working population from 1994 to 2009. The overall mean prevalence of employment of people with epilepsy was 5.1±0.2 per 1000 workers. The employment rate among people with epilepsy increased from 63.5% in 1994 to 65.9% in 2000 (0.4% annually) and then more steeply from 66.8% in 2001 to 76.9% in 2009 (1.4% annually). A prominent increase in rate of employment of people with epilepsy since 2001 was temporarily associated with approval of leviteracetam in 2000 (P<0.001, OR=8.3, CI=6.45-10.12). The overall mean employment rate of people with epilepsy was lower than that of the general population (68.5% vs 90.1%, P<0.001). The overall mean incidence of epilepsy-related retirement (RI) during the study was 4.6±1.6/1000, similar to the RI for people with other illnesses (5.1±0.8/1000), and the risk of retiring because of epilepsy was not higher than that for other illnesses over the entire study period (P=0.52, OR=1.11, CI=0.86-1.43). The RI among workers with epilepsy, however, sharply declined from 8.3/1000 in 1994 to 2.9/1000 in 2000 (-65%, < 0.001), followed by a slight increase and stabilization at 3.9/1000 workers between 2001 and 2009. The decline in RI among people with epilepsy was temporarily associated with legislation of the Law on Support of Employment in 1996 (P=0.032, OR=2.15, CI=1.17-2.89) and approval of lamotrigine in 1993 (P=0.024, OR=2.64, CI=2.17-3.88). These patterns suggest that drug treatment and legislative laws may have led to increased employment and reduced retirement rates for people with epilepsy.
authors.affiliation: Clinic of Neurology, Marienhospital Kevelaer, Basilika Strasse 55, Kevelaer, Germany. alexei.korchounov@medizin.uni-halle.de
authors.forename: A
authors.initials: A
authors.lastname: Korchounov
authors.forename: T
authors.initials: T
authors.lastname: Tabatadze
authors.forename: D
authors.initials: D
authors.lastname: Spivak
authors.forename: W
authors.initials: W
authors.lastname: Rössy
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D015331:Cohort Studies; D017281:Cost of Illness; D006233:Persons with Disabilities / Q000706:statistics & numerical data; D004651:Employment / Q000706:statistics & numerical data*; D004827:Epilepsy / Q000453:epidemiology* / Q000523:psychology; D005260:Female; D005858:Germany / Q000453:epidemiology; D006020:Glycopeptides; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D012016:Reference Values; D012179:Retirement / Q000706:statistics & numerical data*
chemical_list: C523421:AN 0900; D006020:Glycopeptides